Repository logo

Pharmacological and metabolic parameters of [18F]flubrobenguane in clinical imaging populations

Simple item page
dc.contributor.authorMair, Braeden A
dc.contributor.authorZelt, Jason G E
dc.contributor.authorNekesa, Kirabo
dc.contributor.authorSaint-Georges, Zacharie
dc.contributor.authorDinelle, Katie
dc.contributor.authorAdi, Myriam
dc.contributor.authorRobinson, Simon
dc.contributor.authorMielniczuk, Lisa M
dc.contributor.authorShlik, Jakov
dc.contributor.authorBeanlands, Rob S
dc.contributor.authordeKemp, Robert A
dc.contributor.authorRotstein, Benjamin H
dc.date.accessioned2023-10-12T21:03:50Z
dc.date.issued2023
dc.description.abstractCardiac sympathetic nervous system molecular imaging has demonstrated prognostic value. Compared with meta-[11C]hydroxyephedrine, [18F]flubrobenguane (FBBG) facilitates reliable estimation of SNS innervation using similar analytical methods and possesses a more convenient physical half-life. The aim of this study was to evaluate pharmacokinetic and metabolic properties of FBBG in target clinical cohorts.en_US
dc.description.sponsorshipThis study was supported by the Heart and Stroke Foundation of Canada, the Cardiovascular Network of Canada (CANet), and an Ontario Early Researcher Award to B.H.R. This project was also funded by a university-industry partnership grant (RE07-021) from the Ontario Research Fund, Lantheus Medical Imaging, Inc, the University Medical Research Fund, and a Faculty of Medicine Translational Research Grant. B.A.M. is supported by the Natural Science and Engineering Research Council of Canada (NSERC PGS-D). J.G.E.Z. and Z.S. are supported by the Vanier Canada Graduate Scholarship Program. R.S.B. is supported in part by an University of Ottawa Distinguished Chair in Cardiac Imaging Research.en_US
dc.embargo.lift2024-07-26
dc.embargo.terms2024-07-26
dc.identifier.citationJ. Nucl. Cardiol. 2023, 30(5), 2089–2095en_US
dc.identifier.doi10.1007/s12350-023-03338-9en_US
dc.identifier.issn1071-3581en_US
dc.identifier.urihttps://link.springer.com/article/10.1007/s12350-023-03338-9en_US
dc.identifier.urihttps://doi.org/10.1007/s12350-023-03338-9en_US
dc.identifier.urihttp://hdl.handle.net/10393/45542
dc.identifier.urihttps://doi.org/10.20381/ruor-29747
dc.language.isoenen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectFlubrobenguaneen_US
dc.subjectPETen_US
dc.subjectfluorine-18en_US
dc.subjectmetabolismen_US
dc.subjectsympathetic nervous systemen_US
dc.subjectHumansen_US
dc.subjectPositron-Emission Tomographyen_US
dc.subjectHearten_US
dc.subjectGuanidinesen_US
dc.subjectCardiomyopathiesen_US
dc.titlePharmacological and metabolic parameters of [18F]flubrobenguane in clinical imaging populationsen_US
dc.typeResearch Paperen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail ImageThumbnail Image
Name:
Flubrobenguane Metabolism Manuscript - accepted version.pdf
Size:
1.46 MB
Format:
Adobe Portable Document Format
Description:
manuscript and supplemental information
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail ImageThumbnail Image
Name:
license.txt
Size:
4.92 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Biochimie, microbiologie et immunologie // Biochemistry, Microbiology and Immunology